AnalystsMyles MinterMyles Minter's Stock Forecasts
AnalystsMyles Minter
Sectors:
Analyst Ranking
Bottom 22%
#3615 out of 4565 analysts
Average Return
-4.36%
Win Rate
63%5 out of 8
Risk vs Reward
Poor
Good
Myles Minter's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Alnylam Pharmaceuticals IncALNY | +43.99% | $134.01 | $192.96 | 2022-06-06 - 2023-06-06 | Buy |
Larimar Therapeutics IncLRMR | +27.95% | $3.22 | $4.12 | 2022-09-18 - 2023-09-18 | Buy |
Ionis Pharmaceuticals IncIONS | +26.05% | $30.25 | $38.13 | 2021-12-13 - 2022-12-13 | Buy |
Argenx SeARGX | +17.27% | $384.37 | $450.75 | 2022-12-06 - 2023-12-06 | Buy |
Neurocrine Biosciences IncNBIX | +14.11% | $96.93 | $110.61 | 2020-02-23 - 2021-02-24 | Buy |
Myles Minter Analyst Color
Get additional color on Myles Minter's coverage of popular stocks
Myles Minter's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Arcturus Therapeutics Holdings IncARCT | 1 | Buy | $71.00 | +171.30% | Initiates Coverage On | 9 months ago |
Argenx SeARGX | 1 | Buy | N/A | N/A | Initiates Coverage On | a year ago |
Larimar Therapeutics IncLRMR | 1 | Buy | N/A | N/A | Upgrades | 2 years ago |
Alnylam Pharmaceuticals IncALNY | 1 | Buy | N/A | N/A | Initiates Coverage On | 2 years ago |
Ionis Pharmaceuticals IncIONS | 1 | Buy | N/A | N/A | Upgrades | 2 years ago |
Alector IncALEC | 1 | Buy | N/A | N/A | Initiates Coverage On | 3 years ago |
Translate Bio IncTBIO1 | 1 | Hold | N/A | N/A | Downgrades | 3 years ago |
Praxis Precision Medicines IncPRAX | 1 | Buy | N/A | N/A | Initiates Coverage On | 3 years ago |
Neurocrine Biosciences IncNBIX | 1 | Buy | $116.00 | N/A | Initiates Coverage On | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.